Investors · CPL UK

Looking for investment or strategic partners? We're looking for you then!

Whether it's our internal CRO or you're simply looking for investment, we meet with some many players from across the industry and would love to help you connect.

If you want to be listed on this page let us know via the form below or reach out directly; we'll continue to send investors and the likes to this page who are free to contact you directly.

What we need from you:

To fill out the below click here

Company name/Contact details/Relevant links (i.e. website, article, investor page etc)	Intro to the business/pitch (ideally 300 words max)	Looking for… (ideally 150 words max)
Libera Bio S.L. (www.liberabio.com) Contact (CEO): Olivier.Jarry@LiberaBio.com +1 914 703 1073	Libera Bio develops a new family of cancer treatments based on its MPN Technology for nanodelivery to intracellular targets and on novel monoclonal antibodies, with the goal of having them commercialized by large biopharma companies. First technology with in vivo POC of intracellular delivery of whole antibodies. Targetable to specific cells. MPN may combine in a single nanocapsule a mAb and a small molecule. Long stability in plasma and extended release. Excellent diffusivity in organs. Non-active ingredients are FDA/EMA approved and GRAS. Easy to manufacture. May be lyophilized Libera Bio lead candidates are antibodies for KRAS G12D and KRAS G12V delivered by MPN. Each of these mutations is associated with 1 in 4 pancreatic cancers, 1 in 10 colorectal cancers, etc. Both show evidence of efficacy in preclinical models. Both have received a Right Of First Refusal from a top 10 pharma. LIB111 is humanized and is being tested before CMC and IND enabling studies. Combination with MEKi being studied. In addition, Libera Bio is designing 4 other novel antibodies to address intracellular cancer targets: STAT3, CRAF, HIF-1a, HIF-2a. The company is very open to collaborating. It partners / licenses its technology with research centers and biopharma companies in Canada, the USA, the UK, Belgium, France, Spain, in oncology, neurology, inflammation and implantable medical devices.	The company is very open to collaborating. It partners / licenses its technology with research centers and biopharma companies in Canada, the USA, the UK, Belgium, France, Spain, in oncology, neurology, inflammation and implantable medical devices. ... (i) USD 4 million for early stages of new programs, (ii) new collaborations for the targeted delivery of mAbs or small molecules to intracellular targets (cancer and beyond), (iii)out-licensing the KRAS lead mAb for further development

Want to reach out directly? contact cplus@cpl.com or thomas.hancox@cpl.com